The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
260 billion
PE Ratio
21.96 x
Beta (volatility)
0.17
Earnings Per Share
14.57
About
ISIN : CH0012032048
It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology,...
Price
Performance Comparison
| Roche Holding AG Participat... | |
|---|---|
| 1 year return |
+1 %
|
| 5 years return |
+10 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 7.15 | 94 % | 0.67 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 4.16 | 3.56 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
23 years
Frequency
1x / year
Dividends in 2024
March
Dividends in 2023
March
March
Dividends in 2023
March
Forward Annual Amount
$11.01
Ex-dividend
3/28/2025
Financials
Year-over-Year growth
Profitability
Health
News
ASEAN Point of Care Diagnostics Company Evaluation Report 2025 | Abbott, Roche, and Siemens Healthineers Lead with Leadership in Diagnostics, Personalized Care, and AI-Integrated Medical Technologies
8/27/2025
Roche Holding AG's (VTX:ROG) top owners are individual investors with 59% stake, while 33% is held by institutions
8/27/2025
Analog Devices’s Q2 Earnings Call: Our Top 5 Analyst Questions
8/27/2025
PathAI Expands AISight® Dx Primary Diagnosis Clearance to Support VENTANA DP 200 and DP 600 Slide Scanners Through Predetermined Change Control Plan (PCCP)
8/26/2025
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
8/25/2025
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
8/25/2025
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
8/25/2025
Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug
8/25/2025
Health Care Roundup: Market Talk
8/22/2025
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
8/22/2025
Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
8/21/2025
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
8/21/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2025 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.